Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
This is the first part of a case presentation I did with two great colleagues: Dr. Anne Tsao, who is a medical oncologist and lung cancer expert at MD Anderson Cancer Center in Houston, and Dr. Alex Farivar, who is a terrific thoracic surgeon at my own institution, Swedish Cancer Institute in Seattle.
This case is an elderly gentleman who has a very indolent but growing lung lesion. His story brings up questions of how concerned to be in following a nodule in a patient of advanced age and with competing medical issues, whether surgery that is less than a lobectomy might be considered, as well as the systemic therapy options for bronchioloalveolar carcinoma.
I hope that's helpful. We'll provide info on a couple of additional cases from this discussion in the future.
Please feel free to offer comments and raise questions in our
discussion forums.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.